Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

View ORCID ProfileKara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith
doi: https://doi.org/10.1101/2021.12.17.21268009
Kara W. Chew
1Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kara W. Chew
  • For correspondence: kchew@mednet.ucla.edu
Carlee Moser
2Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric S. Daar
3Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Wohl
4Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Z. Li
5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Coombs
6Departments of Laboratory Medicine and and Pathology
7Department of Medicine, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Ritz
8Harvard T.H. Chan School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Giganti
8Harvard T.H. Chan School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arzhang Cyrus Javan
10National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yijia Li
5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Malvestutto
12Ohio State University Wexner Medical Center, Columbus, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Klekotka
13Eli Lilly and Company, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Price
14Eli Lilly and Company, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ajay Nirula
13Eli Lilly and Company, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Fischer
4Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veenu Bala
17UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruy M. Ribeiro
18Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan S. Perelson
18Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtney V. Fletcher
17UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph J. Eron
4Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith S. Currier
1Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Hughes
8Harvard T.H. Chan School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davey M. Smith
24Department of Medicine, University of California, San Diego, La Jolla, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance The antiviral activity and efficacy of anti-SARS-CoV-2 monoclonal antibody (mAb) therapies to accelerate recovery from COVID-19 is important to define.

Objective To determine safety and efficacy of the mAb bamlanivimab to reduce nasopharyngeal (NP) SARS-CoV-2 RNA levels and symptom duration.

Design ACTIV-2/A5401 is a randomized, blinded, placebo-controlled platform trial. Two dose cohorts were enrolled between August 19 and November 17, 2020 for phase 2 evaluation: in the first, participants were randomized 1:1 to bamlanivimab 7000 mg versus placebo, and in the second to bamlanivimab 700 mg versus placebo. Randomization was stratified by time from symptom onset (≤ or >5 days) and risk of progression to severe COVID-19 (“higher” vs “lower”).

Setting Multicenter trial conducted at U.S. sites.

Participants Non-hospitalized adults ≥18 years of age with positive SARS-CoV-2 antigen or nucleic acid test within 7 days, ≤10 days of COVID-19 symptoms, and with oxygen saturation ≥92% within 48 hours prior to study entry.

Intervention Single infusion of bamlanivimab (7000 or 700 mg) or placebo.

Main Outcomes and Measures Detection of NP SARS-CoV-2 RNA at days 3, 7, 14, 21, and 28, time to improvement of all of 13 targeted COVID-19 symptoms by daily self-assessment through day 28, and grade 3 or higher treatment emergent adverse events (TEAEs) through day 28. Secondary measures included quantitative NP SARS-CoV-2 RNA, all-cause hospitalizations and deaths (composite), area under the curve of symptom scores from day 0 through day 28, plasma bamlanivimab concentrations, plasma and serum inflammatory biomarkers, and safety through week 24.

Results Ninety-four participants were enrolled to the 7000 mg cohort and 223 to the 700 mg cohort and initiated study intervention. The proportion meeting protocol criteria for “higher” risk for COVID-19 progression was 42% and 51% for the 7000 and 700 mg cohort, respectively. Median time from symptom onset at study entry for both cohorts was 6 days. There was no difference in the proportion with undetectable NP SARS-CoV-2 RNA at any post-treatment timepoints (risk ratio compared to placebo, 0.82-1.05 for 7000 mg dose [overall p=0.88] and 0.81-1.21 for 700 mg dose [overall p=0.49]), time to symptom improvement (median of 21 vs 18.5 days, p=0.97, for 7000 mg bamlanivimab vs placebo and 24 vs 20.5 days, p=0.08, for 700 mg bamlanivimab vs placebo), or grade 3+ TEAEs with either dose compared to placebo. Median NP SARS-CoV-2 RNA levels were lower at day 3 and C-reactive protein, ferritin, and fibrinogen levels significantly reduced at days 7 and 14 for bamlanivimab 700 mg compared to placebo, with similar trends observed for bamlanivimab 7000 mg. Viral decay modeling supported more rapid decay with bamlanivimab compared to placebo.

Conclusions and Relevance Treatment with bamlanivimab 7000 mg and 700 mg was safe and compared to placebo led to more rapid reductions in NP SARS-CoV-2 RNA and inflammatory biomarkers, but did not decrease time to symptom improvement. The clinical utility of mAbs for outcomes other than hospitalizations and deaths is uncertain.

Trial Registration ClinicalTrials.gov Identifier: NCT04518410

Question What is the safety and efficacy of bamlanivimab monoclonal antibody (mAb) treatment for mild to moderate COVID-19?

Findings In this randomized, placebo-controlled phase 2 trial of 317 non-hospitalized adults with COVID-19, there was no relationship between symptoms or disease progression risk and nasopharyngeal (NP) virus shedding. Bamlanivimab was safe and reduced NP SARS-CoV-2 RNA levels and inflammatory biomarker levels more than placebo, but did not shorten symptom duration.

Meaning Nasal virus shedding was not associated with symptoms or baseline risk factors for severe COVID-19. Bamlanivimab, which has been associated with reduced hospitalizations in high-risk individuals, demonstrated antiviral activity with early post-treatment NP sampling but did not accelerate symptom improvement. The clinical utility of bamlanivimab for outcomes other than hospitalizations and deaths, including longer-term outcomes, is uncertain.

Competing Interest Statement

KWC has received research funding to the institution from Merck Sharp & Dohme. ESD receives consulting fees from Gilead Sciences and Merck and research support through the institution from Gilead Sciences and ViiV. DAW has received funding to the institution to support research and honoraria for advisory boards and consulting from Gilead Sciences. JZL has consulted for Abbvie. ASP has consulted for Amphylx Pharmaceticals. C. Malvestutto has received research funding to the institution from Eli Lilly. PK, KP, and AN are employees and shareholders of Eli Lilly. WF has received research funding from Ridgeback Biopharmaceuticals, served on adjudication committees for Janssen, Syneos, and consulted for Roche and Merck. JJE is an ad hoc consultant to GSK/VIR, data monitoring committee (DMC) chair for Adagio Phase III studies. DMS has consulted for the following companies Fluxergy, Kiadis, Linear Therapies, Matrix BioMed, Arena Pharmaceuticals, VxBiosciences, Model Medicines, Bayer Pharmaceuticals, Signant Health and Brio Clinical.

Clinical Trial

NCT04518410

Funding Statement

This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number 3UM1AI068636-14S2, UM1 AI068634, UM1 AI068636 and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Portions of this work were performed at Los Alamos National Laboratory under the auspices of the US Dept. of Energy under contract 89233218CNA000001 and supported by NIH grants R01-AI028433, R01-OD011095 (ASP), and Los Alamos National Laboratory LDRD 20200743ER, 20200695ER, and 20210730ER. Study medication was donated by Eli Lilly and Company.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Advarra IRB gave ethical approval for this work (Pro00045266).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • For the ACTIV-2/A5401 Study Team

Data Availability

The authors confirm that all data underlying the findings are fully available. Due to ethical restrictions, study data are available upon request from sdac.data@sdac.harvard.edu with the written agreement of the AIDS Clinical Trials Group and the manufacturer of the investigational product.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
Kara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith
medRxiv 2021.12.17.21268009; doi: https://doi.org/10.1101/2021.12.17.21268009
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
Kara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith
medRxiv 2021.12.17.21268009; doi: https://doi.org/10.1101/2021.12.17.21268009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (519)
  • Anesthesia (124)
  • Cardiovascular Medicine (1407)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (580)
  • Epidemiology (10264)
  • Forensic Medicine (6)
  • Gastroenterology (526)
  • Genetic and Genomic Medicine (2611)
  • Geriatric Medicine (253)
  • Health Economics (495)
  • Health Informatics (1727)
  • Health Policy (788)
  • Health Systems and Quality Improvement (669)
  • Hematology (266)
  • HIV/AIDS (563)
  • Infectious Diseases (except HIV/AIDS) (12066)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (272)
  • Medical Ethics (83)
  • Nephrology (286)
  • Neurology (2448)
  • Nursing (143)
  • Nutrition (374)
  • Obstetrics and Gynecology (486)
  • Occupational and Environmental Health (565)
  • Oncology (1314)
  • Ophthalmology (397)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (341)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (328)
  • Primary Care Research (294)
  • Psychiatry and Clinical Psychology (2390)
  • Public and Global Health (4987)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (520)
  • Respiratory Medicine (680)
  • Rheumatology (307)
  • Sexual and Reproductive Health (253)
  • Sports Medicine (244)
  • Surgery (296)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)